1-[(2-arylthiazol-4-yl)methyl]azoles as a new class of anticonvulsants: Design, synthesis, in vivo screening, and in silico drug-like properties

Chemical Biology and Drug Design

Volumn 78, Issue 5, 2011, Pages 844-852

  Ahangar, Nematollah ^a   Ayati, Adile ^b   Alipour, Eskandar ^b   Pashapour, Arsalan ^a   Foroumadi, Alireza ^c   Emami, Saeed ^a  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

(arylalkyl)azoles; 1,2,4 triazole; 1H imidazole; Anticonvulsant; Drug likeness; Thiazole

Indexed keywords

1 [(2 (4 CHLOROPHENYL)THIAZOL 4 YL)METHYL] 1H IMIDAZOLE; 1 [(2 (4 CHLOROPHENYL)THIAZOL 4 YL)METHYL] 2 METHYL 1H IMIDAZOLE; 1 [(2 ARYLTHIAZOL 4 YL)METHYL]AZOLE; 1 [(2 PHENYLTHIAZOL 4 YL)METHYL] 1H 1,2,4 TRIAZOLE; 1 [(2 PHENYLTHIAZOL 4 YL)METHYL] 1H BENZO[D]IMIDAZOLE; 1 [(2 PHENYLTHIAZOL 4 YL)METHYL] 1H IMIDAZOLE; 1 [[2 (4 CHLOROPHENYL)THIAZOL 4 YL]METHYL] 1H 1,2,4 TRIAZOLE; 1 [[2 (4 CHLOROPHENYL)THIAZOL 4 YL]METHYL] 1H BENZO[D]IMIDAZOLE; 1 [[2 (4 CHLOROPHENYL)THIAZOL 4 YL]METHYL] 1H IMIDAZOLE; 2 METHYL 1 [(2 PHENYLTHIAZOL 4 YL)METHYL] 1H IMIDAZOLE; 4 (CHLOROMETHYL) 2 (4 CHLOROPHENYL)THIAZOLE; 4 (CHLOROMETHYL) 2 PHENYLTHIAZOLE; 4 AMINO 1 [(2 PHENYLTHIAZOL 4 YL)METHYL] 4H 1,2,4 TRIAZOLIUM CHLORIDE; 4 AMINO 1 [[2 (4-CHLOROPHENYL)THIAZOL 4 YL]METHYL] 4H 1,2,4 TRIAZOLIUM CHLORIDE; ANTICONVULSIVE AGENT; PENTETRAZOLE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; COMPUTER MODEL; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; ELECTRIC SHOCK; HYDROGEN BOND; IN VIVO STUDY; MALE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTICONVULSANTS; AZOLES; BLOOD-BRAIN BARRIER; DRUG DESIGN; MALE; MICE; SEIZURES;

MUS;

EID: 80054091085     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01211.x     Document Type: Article

References (36)

1. Mc Namara O.J. (2006) Drugs effective in the therapy of the epilepsies. In: Brunton L.L., Lazo J.S., Parker K.L., editors. The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; p. 501-526.
2. Strine T.W., Kobau R., Chapman D.P., Thurman D.J., Price P., Balluz L.S. (2005) Psychological distress, comorbidities, and health behaviors among U.S. adults with seizures: results from the 2002 National Health Interview Survey. Epilepsia;46:1133-1139.
3. Mccorry D., Chadwick D., Marson A. (2004) Current drug treatment of epilepsy in adults. Lancet Neurol;3:729-735.
4. Löscher W., Schmidt D. (2002) New horizons in the development of antiepileptic drugs. Epilepsy Res;50:3-16.
5. Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Perucca E., Tomson T. (2004) Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res;61:1-48.
6. Gatti G., Bonomi I., Jannuzzi G., Perucca E. (2000) The new antiepileptic drugs: pharmacological and clinical aspects. Curr Pharm Des;6:839-860.
7. Edafiogho I., Scott K.R. (1996) In: Wolff M.E., editor. Burger's Medicinal Chemistry and Drug Discovery, 5th edn, Vol. 3. New York: John Wiley & Sons, Inc; p. 175-260.
8. Malawska B. (2005) New anticonvulsant agents. Curr Top Med Chem;5:69-85.
9. Walker K.A.M., Wallach M.B., Hirschfeld D.R. (1981) 1-(Naphthylalkyl)-1H-imidazole derivatives, a new class of anticonvulsant agents. J Med Chem;24:67-74.
10. Nardi D., Tajana A., Leonardi A., Pennini R., Portioli F., Magistretti M.J., Subissi A. (1981) Synthesis and anticonvulsant activity of N-(benzoylalkyl)imidazoles and N-(omega-phenyl-omega-hydroxyalkyl)imidazoles. J Med Chem;24:727-731.
11. Johnston G.A.R. (2002) Medicinal chemistry and molecular pharmacology of GABA(C) receptors. Curr Top Med Chem;2:903-913.
12. Ashton D., Fransen J., Heeres J., Clincke G.H., Janssen P.A. (1992) In vivo studies on the mechanism of action of the broad spectrum anticonvulsant loreclezole. Epilepsy Res;11:27-36.
13. Robertson D.W., Beedle E.E., Lawson R., Leander J.D. (1987) Imidazole anticonvulsants: structure-activity relationships of [(biphenylyloxy)alkyl]imidazoles. J Med Chem;30:939-943.
14. Lankau H.-J., Unverferth K., Grunwald C., Hartenhauer H., Heinecke K., Bernöster K., Dost R., Egerland U., Rundfeldt C. (2007) New GABA-modulating 1, 2, 4-oxadiazole derivatives and their anticonvulsant activity. Eur J Med Chem;42:873-879.
15. Emami S., Kebriaeezadeh A., Zamani M.J., Shafiee A. (2006) Azolylchromans as a novel scaffold for anticonvulsant activity. Bioorg Med Chem Lett;16:1803-1806.
16. Kebriaeezadeh A., Emami S., Ebrahimi M., Sharifzadeh M., Khorasani R., Shafiee A. (2008) Anticonvulsant and antiepileptogenic effects of azolylchromanones on lithium-pilocarpine induced seizures and pentylenetetrazole-kindling model of epilepsy. Biomed Pharmacother;62:208-211.
17. Rai N.P., Venu T.D., Manuprasad B.K., Shashikanth S., Arunachalam P.N., Firdouse A. (2010) Synthesis of some novel 2-[2-(aroyl-aroxy)-methyl]-4-phenyl-1, 3-thiazoles as potent anti-inflammatory agents. Chem Biol Drug Des;75:400-406.
18. DeSarro G.B., Zapalla M., Grasso S., Chimirri A., DeSarro A. (1993) Molecular requirement for anticonvulsant activity in a series of thiazolo-1, 4-benzodiazepine derivatives and comparison with classical benzodiazepines. Gen Pharmacol;24:877-884.
19. Qin J., Xi L., Du J., Liu H., Yao X. (2010) QSAR studies on aminothiazole derivatives as aurora A kinase inhibitors. Chem Biol Drug Des;76:527-537.
20. Bineshmarvasti M., Sharifzadeh M., Jalilian A.R., Soltaninejad K., Shafiee A. (2003) Syntheses and anticonvulsant activity of N4-substituted triazolylthiazoles. Daru;11:74-78.
21. Chaturvedi A.K., Barthwal J.P., Parmar S.S., Stenberg V.I. (1975) Anticonvulsant activity of N, N'-bis[3-(3-substituted urea)propyl]piperazines. J Pharm Sci;64:454-456.
22. Krall R.L., Penry J.K., White B.G., Kupferberg H.J., Swinyard E.A. (1978) Antiepileptic drug development: II. Anticonvulsant drug screening. Epilepsia;19:409-428.
23. Zhao Y., Abraham M.H., Lee J., Hersey A., Luscombe N.C., Beck G., Sherborne B., Cooper I. (2002) Rate-limited steps of human oral absorption and QSAR studies. Pharm Res;19:1446-1457.
24. Clark D.E. (1999) Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. J Pharm Sci;88:815-821.
25. Mahmoodi M., Aliabadi A., Emami S., Safavi M., Rajabalian S., Mohagheghi M.A., Khoshzaban A., Samzadeh-Kermani A., Lamei N., Shafiee A., Foroumadi A. (2010) Synthesis and in-vitro cytotoxicity of poly-functionalized 4-(2-arylthiazol-4-yl)-4H-chromenes. Arch Pharm Chem Life Sci;343:411-416.
26. Emami S., Foroumadi A., Falahati M., Lotfali E., Rajabalian S., Ebrahimi S.-A., Farahyar S., Shafiee A. (2008) 2-Hydroxyphenacyl azoles and related azolium derivatives as antifungal agents. Bioorg Med Chem Lett;18:141-146.
27. Löscher W. (2002) Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy. Epilepsy Res;50:105-123.
28. Gasior M., Ungard J.T., Witkin J.M. (2000) Chlormethiazole: effectiveness against toxic effects of cocaine in mice. J Pharmacol Exp Ther;295:153-161.
29. Proudfoot J.R. (2002) Drugs, leads, and drug-likeness: an analysis of some recently launched drugs. Bioorg Med Chem Lett;12:1647-1650.
30. Muegge I. (2003) Selection criteria for drug-like compounds. Med Res Rev;23:302-321.
31. Lipinski C.A. (2004) Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Tech;1:337-341.
32. Ertl P., Rohde B., Selzer P. (2000) Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem;43:3714-3717.
33. Clark D.E., Pickett S.D. (2000) Computational methods for the prediction of 'drug-likeness'. Drug Discov Today;5:49-58.
34. George A. (1999) The design and molecular modeling of CNS drugs. Curr Opin Drug Discov Dev;2:286-292.
35. van de Waterbeemd H., Camenisch G., Folkers G., Chretien J., Raevsky O. (1998) Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J Drug Target;6:151-165.
36. Abraham M.H., Takács-Novák K., Mitchell R.C. (1997) On the partition of ampholytes: application to blood-brain distribution. J Pharm Sci;86:310-315.